Comparison of the effect on glycemic control between once-daily semaglutide and DPP-4 inhibitors in patients with type 2 diabetes -prospective randomized controlled trial- (SWITCH SEMA-2 study)

omoto Hiroshi0 个研究点目标入组 172 人开始时间: 2021年8月26日最近更新: 2023年10月17日

试验速览

暂无简介。

•1) Age 20-90 years old
•2) HbA1c 7.0-10.0%
•3) BMI >= 18.5 kg/m2
•4) patients who were treated with DPP-4 inhibitors at least for 12 weeks without discontinuation for more than 1 week (SItagliptin, teneligliptin, and anagliptin: from regular dose to maximun dose; vildagliptin, saxagliptin, trelagliptin, linagliptin, alogliptin, and omarigliptin: regular dose)
•5) written informed consent

•1) treatment with GLP-1 receptor agonists within past 12 weeks
•2) history of anaphylaxis of semaglutide
•3) unstable retinopathy
•4) severe hepatic dysfunction or renal dysfunction
•5) severe ketosis, diabetic coma
•6) severe infection, surgery, serious trauma
•7) female patients who are pregnant, lactating and/or willing to be pregnant, or male patients who wants to impregnate partner during study period
•8) patients who are inadequate to enter this study due to the other reasons by physician's judgments

发起方

omoto Hiroshi